## INSTRUCTIONS FOR USE

This Clinical Policy provides assistance in interpreting Oxford benefit plans. Unless otherwise stated, Oxford policies do not apply to Medicare Advantage members. Oxford reserves the right, in its sole discretion, to modify its policies as necessary. This Clinical Policy is provided for informational purposes. It does not constitute medical advice. The term Oxford includes Oxford Health Plans, LLC and all of its subsidiaries as appropriate for these policies.

When deciding coverage, the member specific benefit plan document must be referenced. The terms of the member specific benefit plan document [e.g., Certificate of Coverage (COC), Schedule of Benefits (SOB), and/or Summary Plan Description (SPD)] may differ greatly from the standard benefit plan upon which this Clinical Policy is based. In the event of a conflict, the member specific benefit plan document supersedes this Clinical Policy. All reviewers must first identify member eligibility, any federal or state regulatory requirements, and the member specific benefit plan coverage prior to use of this Clinical Policy. Other Policies may apply.

UnitedHealthcare may also use tools developed by third parties, such as the MCG™ Care Guidelines, to assist us in administering health benefits. The MCG™ Care Guidelines are intended to be used in connection with the independent professional medical judgment of a qualified health care provider and do not constitute the practice of medicine or medical advice.

## CONDITIONS OF COVERAGE

<table>
<thead>
<tr>
<th>Applicable Lines of Business/ Products</th>
<th>This policy applies to Oxford Commercial plan membership.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Benefit Type</td>
<td>Medical</td>
</tr>
<tr>
<td>Referral Required</td>
<td>No</td>
</tr>
<tr>
<td>(Does not apply to non-gatekeeper products)</td>
<td></td>
</tr>
<tr>
<td>Authorization Required</td>
<td>Yes¹</td>
</tr>
<tr>
<td>(Precertification always required for inpatient admission)</td>
<td></td>
</tr>
<tr>
<td>Precertification with Medical Director Review Required</td>
<td>Yes¹</td>
</tr>
<tr>
<td>Applicable Site(s) of Service</td>
<td>Outpatient</td>
</tr>
<tr>
<td>(If site of service is not listed, Medical Director review is required)</td>
<td></td>
</tr>
<tr>
<td>Special Considerations</td>
<td>¹Precertification through Oxford’s Medical Management Department, with review by a Medical Director or their designee, is required.</td>
</tr>
</tbody>
</table>

Related Policy
- Acquired Rare Disease Drug Therapy Exception Process
- Specialty Medication Administration – Site of Care Review Guidelines

---

**EXONDYS 51™ (ETEPLIRSEN)**

**Policy Number:** PHARMACY 294.2 T2  
**Effective Date:** April 1, 2017
**BENEFIT CONSIDERATIONS**

Before using this policy, please check the member specific benefit plan document and any federal or state mandates, if applicable.

Some Certificates of Coverage allow for coverage of experimental/investigational/unproven treatments for life-threatening illnesses when certain conditions are met. The member-specific benefit plan document must be consulted to make coverage decisions for this service. Some states mandate benefit coverage for off-label use of medications for some diagnoses or under some circumstances when certain conditions are met. Where such mandates apply, they supersede language in the benefit document or in the medical or drug policy. Benefit coverage for an otherwise unproven service for the treatment of serious rare diseases may occur when certain conditions are met. Refer to the policy titled *Acquired Rare Disease Drug Therapy Exception Process*.

**Essential Health Benefits for Individual and Small Group**

For plan years beginning on or after January 1, 2014, the Affordable Care Act of 2010 (ACA) requires fully insured non-grandfathered individual and small group plans (inside and outside of Exchanges) to provide coverage for ten categories of Essential Health Benefits (“EHBs”). Large group plans (both self-funded and fully insured), and small group ASO plans, are not subject to the requirement to offer coverage for EHBs. However, if such plans choose to provide coverage for benefits which are deemed EHBs, the ACA requires all dollar limits on those benefits to be removed on all Grandfathered and Non-Grandfathered plans. The determination of which benefits constitute EHBs is made on a state by state basis. As such, when using this policy, it is important to refer to the member specific benefit plan document to determine benefit coverage.

**COVERAGE RATIONALE**

**Exondys 51™ (eteplirsen) may be covered for the treatment of Duchenne muscular dystrophy (DMD) in patients who meet ALL of the following criteria:**

- **For initial therapy, ALL of the following:**
  - **One of the following:**
    - Diagnosis of Duchenne muscular dystrophy by a neurologist with expertise in the diagnosis of DMD
    - Diagnosis of Duchenne muscular dystrophy by a physician in consultation with a neurologist with expertise in the diagnosis of DMD
  - **Submission of medical records (e.g., chart notes, laboratory values) confirming the mutation of the DMD gene is amenable to exon 51 skipping; and**
  - **Submission of medical records (e.g., chart notes, laboratory values) confirming patient has a 6-Minute Walk Time (6MWT) ≥ 300 meters while walking independently prior to beginning Exondys 51 therapy.**
  - **One of the following:**
    - Exondys 51 is prescribed by a neurologist with expertise in the treatment of DMD
    - Exondys 51 is prescribed by a physician in consultation with a neurologist with expertise in the treatment of DMD
  - **Exondys 51 dosing for DMD is in accordance with the United States Food and Drug Administration approved labeling: maximum dosing of 30 mg/kg infused once weekly; and Initial authorization will be for no more than 4 weeks**

- **For continuation therapy, ALL of the following:**
  - **One of the following:**
    - Exondys 51 is prescribed by a neurologist with expertise in the treatment of DMD
    - Exondys 51 is prescribed by a physician in consultation with a neurologist with expertise in the treatment of DMD
  - **Submission of medical records (e.g., chart notes) confirming that the patient is ambulatory without needing an assistive device (e.g., cane, walker, wheelchair, etc.). and**
  - **Exondys 51 dosing for DMD is in accordance with the United States Food and Drug Administration approved labeling: maximum dosing of 30 mg/kg infused once weekly; and**
  - **Reauthorization will be for no more than 6 months**

**Exondys 51 will not be covered for other forms of muscular dystrophy.**

---

1. This policy applies to Exondys 51™ (Eteplirsen) for Duchenne muscular dystrophy (DMD) as defined by the United States Food and Drug Administration (FDA). The FDA approval is based on the ability of Exondys 51™ to increase the number of dystrophin molecules within skeletal and cardiac muscle for patients with DMD who have a deletion of the DMD gene in which a mutation is amenable to exon 51 skipping. Exondys 51™ is not approved for other forms of muscular dystrophy (MD) and is not intended for use in myopathy, myasthenia gravis, or any other neuromuscular condition. The decision to use Exondys 51™ for the treatment of other forms of MD or for any other indication is left to the physician and patient. It is important to consult with a qualified healthcare provider before initiating any treatment with Exondys 51™.

---

Exondys 51™ (Eteplirsen)
UnitedHealthcare Oxford Clinical Policy
©1996-2017, Oxford Health Plans, LLC
Effective 04/01/2017
Exondys 51 is indicated for the treatment of Duchenne muscular dystrophy (DMD) in patients who have a confirmed mutation of the DMD gene that is amenable to exon 51 skipping. This indication is approved under accelerated approval based on an increase in dystrophin in skeletal muscle observed in some patients treated with Exondys 51. A clinical benefit of Exondys 51 has not been established. Continued approval for this indication may be contingent upon verification of a clinical benefit in confirmatory trials.1

BACKGROUND

Duchenne muscular dystrophy (DMD) is an X-linked disease that affects 1 in 3,600 – 6,000 live male births. DMD occurs as a result of mutations (mainly deletions) in the dystrophin gene. These mutations lead to an absence or a defect of the protein, dystrophin, resulting in progressive muscle degeneration, leading to loss of ambulation and additional respiratory, orthopedic, and cardiac complications. If left untreated, mean age of death is approximately 19 years of age.2-4

Exondys 51™ (eteplirsen) is an antisense oligonucleotide of the phosphorodiamidate morpholino oligomer (PMO) subclass. PMOs are synthetic molecules in which the five-membered ribofuranosyl rings found in natural DNA and RNA are replaced by a six-membered morpholino ring. Each morpholino ring is linked through an uncharged phosphorodiamidate moiety rather than the negatively charged phosphate linkage that is present in natural DNA and RNA. Each phosphorodiamidate morpholino subunit contains one of the heterocyclic bases found in DNA (adenine, cytosine, guanine, or thymine). Eteplirsen contains 30 linked subunits.1

Eteplirsen is designed to bind to exon 51 of dystrophin pre-mRNA, resulting in exclusion of this exon during mRNA processing in patients with genetic mutations that are amenable to exon 51 skipping. Exon skipping is intended to allow for production of an internally truncated dystrophin protein.1

APPLICABLE CODES

The following list(s) of procedure and/or diagnosis codes is provided for reference purposes only and may not be all inclusive. Listing of a code in this policy does not imply that the service described by the code is a covered or non-covered health service. Benefit coverage for health services is determined by the member specific benefit plan document and applicable laws that may require coverage for a specific service. The inclusion of a code does not imply any right to reimbursement or guarantee claim payment. Other Policies may apply.

<table>
<thead>
<tr>
<th>ICD-10 Diagnosis Code</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>G71.0</td>
<td>Muscular dystrophy</td>
</tr>
</tbody>
</table>

CLINICAL EVIDENCE

Eteplirsen is indicated for the treatment of Duchenne muscular dystrophy (DMD) in patients who have a confirmed mutation of the DMD gene that is amenable to exon 51 skipping.1

Mendell et al evaluated eteplirsen for the treatment of DMD in a small (n=12), randomized, multi-center, double-blind, placebo-controlled study, receiving weekly infusions of either placebo, eteplirsen 30 mg/kg or eteplirsen 50 mg/kg for 24 weeks.1,6 Following the 24-week study, placebo/delayed patients switched to an open-label extension treatment with either dosing of eteplirsen regimen. Outcome measures assessed the primary outcome of eteplirsen-induced dystrophin production, as well as the 6-minute walk test (6MWT, reported as 6-minute walk distance, 6MWD). Patients had a mean age of 9.4 years, and a mean 6MWD at baseline of 363 meters, and were on a stable dose of corticosteroids for at least 6 months. The patients participating in the extension study were compared to an external control group. At 180 weeks of treatment, eleven patients underwent a muscle biopsy to analyze for dystrophin protein. The average dystrophin protein level after 180 weeks of treatment was 0.93% of the dystrophin level in healthy subjects. At week 24, the 30 mg/kg eteplirsen patients were biopsied, and percentage of dystrophin-positive fibers increased to 23% of normal vs. placebo (p≤0.002). At week 48, there was a 52% and 43% (in the 30 and 50 mg/kg/wk cohorts, respectively), which suggests that dystrophin increases with longer treatment. Restoration of function dystrophin was confirmed by detection of sarcoglycans and neuronal nitric oxide synthase at the sarcolemma. Ambulation-evaluable eteplirsen-treated patients experienced a 67.3 meter benefit compared to placebo patients (p≤0.001). The investigators concluded that eteplirsen restored dystrophin in the 30 and 50 mg/kg/wk cohorts, and in subsequently treated placebo subjects. According to the prescribing information, however, this study failed to provide evidence of a clinical benefit of eteplirsen.

Eteplirsen has not been studied in DMD that is not amenable to exon 51 skipping, nor in other forms of muscular dystrophy (e.g., Becker muscular dystrophy).1
REFERENCES

The foregoing Oxford policy has been adapted from an existing UnitedHealthcare Pharmacy, Clinical Pharmacy Program that was researched, developed and approved by the UnitedHealth Group National Pharmacy & Therapeutics Committee. [2017D0058]


POLICY HISTORY/REVISION INFORMATION

<table>
<thead>
<tr>
<th>Date</th>
<th>Action/Description</th>
</tr>
</thead>
</table>
| 04/01/2017 | - Revised coverage rationale/coverage criteria for the treatment of Duchenne muscular dystrophy (DMD): **Initial Therapy**  
  o Replaced criterion requiring "diagnosis of Duchenne muscular dystrophy" with "diagnosis of Duchenne muscular dystrophy by a neurologist with expertise in the diagnosis of DMD or by a physician in consultation with a neurologist with expertise in the diagnosis of DMD"  
  o Added criterion requiring:  
    ▪ Submission of medical records (e.g., chart notes, laboratory values) confirming the patient has a 6-Minute Walk Time (6MWT) ≥ 300 meters while walking independently prior to beginning Exondys 51 therapy  
    ▪ **One** of the following:  
      - Exondys 51 is prescribed by a neurologist with expertise in the treatment of DMD  
      - Exondys 51 is prescribed by a physician in consultation with a neurologist with expertise in the treatment of DMD  
  **Continuation Therapy**  
  o Added criterion requiring:  
    ▪ **One** of the following:  
      - Exondys 51 is prescribed by a neurologist with expertise in the treatment of DMD  
      - Exondys 51 is prescribed by a physician in consultation with a neurologist with expertise in the treatment of DMD  
    ▪ Submission of medical records (e.g., chart notes) confirming that the patient is ambulatory **without** needing an assistive device (e.g., cane, walker, wheelchair, etc.)  
  - Updated supporting information to reflect the most current references  
  - Archived previous policy version PHARMACY 294.1 T2 |